Compare DNN & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DNN | TRVI |
|---|---|---|
| Founded | 1954 | 2011 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Other Metals and Minerals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 1.9B |
| IPO Year | 1998 | 2019 |
| Metric | DNN | TRVI |
|---|---|---|
| Price | $2.21 | $13.65 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 15 | 11 |
| Target Price | $4.73 | ★ $28.18 |
| AVG Volume (30 Days) | ★ 26.8M | 2.6M |
| Earning Date | 11-03-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 31.91 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $321.58 | N/A |
| Revenue Next Year | $38.26 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.10 | $9.82 |
| 52 Week High | $4.43 | $20.22 |
| Indicator | DNN | TRVI |
|---|---|---|
| Relative Strength Index (RSI) | 36.99 | 49.73 |
| Support Level | $2.10 | $13.08 |
| Resistance Level | $3.43 | $13.55 |
| Average True Range (ATR) | 0.12 | 0.60 |
| MACD | 0.03 | 0.27 |
| Stochastic Oscillator | 23.44 | 76.06 |
Denison Mines Corp is engaged in uranium mining-related activities, including the acquisition, exploration, development, and mining of uranium-bearing properties, as well as the processing, sale, and investment in uranium. The company's key properties include Wheeler River, Waterbury Lake, McClean Lake, Midwest, and others. It operates through two segments: the Mining segment and the Corporate and Other segment. The majority of the company's revenue is generated from the Mining segment, which includes activities related to exploration, evaluation, and development, mining, milling (including toll milling), and the sale of mineral concentrates.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio.